Showing results (61-70 of 119) with videos related to

Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|November 27, 2001
Quality of life measurement in oncology--a matter of the assessment instrument?B Holzner, G Kemmler, B Sperner-Unterweger, et al.
ESMO Open|August 9, 2021
Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literatureR Heregger, F Huemer, G Hutarew, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 1999
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trialG Krajnik, W Wein, R Greil, et al.
Lung Cancer (Amsterdam, Netherlands)|July 22, 2014
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial)F Kocher, A Pircher, A Mohn-Staudner, et al.
Molecular Immunology|November 1, 1988
Importance of an 85 kDa membrane glycoprotein for a variety of cell-cell interactionsT F Schulz, W Vogetseder, M Mitterer, et al.
The Pharmacogenomics Journal|January 20, 2019
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
British Journal of Cancer|April 14, 2015
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trialF Fitzal, M Filipits, M Rudas, et al.
The Pharmacogenomics Journal|July 19, 2017
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
ESMO Open|February 6, 2026
Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trialT Fuereder, K Klinghammer, D Hahn, et al.
BMC Cancer|May 8, 2020
Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive TrialV Bjelic-Radisic, F Fitzal, M Knauer, et al.
Pageof 12